Enovis (NYSE:ENOV) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a research report report published on Sunday morning.

A number of other research firms have also recently commented on ENOV. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. William Blair initiated coverage on Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. BTIG Research boosted their target price on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company dropped their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Evercore reiterated an “outperform” rating and set a $36.00 price target on shares of Enovis in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average price target of $45.17.

Enovis Price Performance

Shares of NYSE:ENOV opened at $26.52 on Friday. The company has a market capitalization of $1.53 billion, a P/E ratio of -1.33 and a beta of 1.41. The company’s 50-day moving average is $23.86 and its 200 day moving average is $25.80. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. Enovis has a fifty-two week low of $21.00 and a fifty-two week high of $37.85.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts forecast that Enovis will post 3.62 earnings per share for the current year.

Insider Transactions at Enovis

In other news, insider Oliver Engert acquired 1,000 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was purchased at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the acquisition, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders bought a total of 5,000 shares of company stock worth $121,983 over the last three months. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds have recently bought and sold shares of ENOV. Arax Advisory Partners purchased a new position in shares of Enovis during the fourth quarter worth approximately $29,000. Farther Finance Advisors LLC boosted its stake in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after purchasing an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. GAMMA Investing LLC raised its position in Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in Enovis by 235.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after purchasing an additional 1,195 shares during the period. Institutional investors own 98.45% of the company’s stock.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported first-quarter EPS of $0.89, topping estimates of $0.82, while revenue of $589.15 million also beat expectations. Revenue rose 5.4% year over year, signaling solid demand and execution. Article Title
• Positive Sentiment: The company reaffirmed 2026 free cash flow conversion of greater than 25%, suggesting management still sees healthy cash generation despite Middle East and tariff headwinds. Article Title
• Neutral Sentiment: Enovis also reiterated full-year 2026 guidance, with EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, which was roughly in line with analyst expectations and may reassure investors about the company’s near-term outlook. Article Title
• Neutral Sentiment: Wells Fargo lowered its price target on Enovis to $40 from $42, but kept an overweight rating, indicating continued upside potential despite a slightly more cautious valuation view. Article Title

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.